ArticleArchives of rheumatology2024
Difficult-to-treat axial spondyloarthritis patients.
Article in Archives of rheumatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Observational
- An Evaluation of Factors Contributing to Primary Nonresponse to Biological Therapy in Patients with Spondyloarthropathy: A Retrospective Cohort Study.Archives of rheumatology · 2026Article
- Prevalence and risk factors of difficult-to-treat axial spondyloarthritis: Real-life evidence from the BioSTaR database.Clinical rheumatology · 2026Observational
- Frequency of difficult-to-manage and treatment-refractory axial SpA: insights from the German RABBIT-SpA register using recent ASAS definitions.Rheumatology (Oxford, England) · 2026Article
- Prevalence and clinical factors associated with difficult-to-manage axial spondyloarthritis: a multicentre Italian cohort study with meta-analysis.Therapeutic advances in musculoskeletal disease · 2026Article
- Patients with poorer health status are more likely to have difficult-to-manage axial spondyloarthritis: insights from a real-world cohort.Therapeutic advances in musculoskeletal disease · 2026Article
- Exploring difficult-to-manage axial spondyloarthritis: results from a Dutch clinical practice registry.Rheumatology (Oxford, England) · 2025Article
- Difficult-to-Manage Axial Spondyloarthritis.Mediterranean journal of rheumatology · 2024Review
- Adherence, Fears, and Beliefs about Biologic Drugs in Rheumatoid Arthritis Patients: A North African Pilot Study.Mediterranean journal of rheumatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to formulate D2T (difficult to treat) criteria for axial spondyloarthritis (AxSpA) patients and identify the prevalence of D2T patients and their characteristics. Patients and methods: The cross-sectional study was conducted with 166 AxSpA patients (93 males, 73 females; mean age: 47.1±12.9 years; range, 19 to 78 years) between February 2023 and March 2023. The criteria were based on patients treated according to the European Alliance of Associations for Rheumatology (EULAR) recommendations for AxSpA. Entry criteria were treatment failure to ≥2 biological/targeted synthetic disease-modifying antirheumatic drugs with two different mechanisms of action or ≥3 biological/targeted synthetic disease-modifying antirheumatic drugs. Potential preliminary factors for D2T criteria were analyzed, and the characteristics of the subjects matching D2T criteria were compared with those of others. Results: One hundred forty-two ankylosing spondylitis patients and 24 nonradiographic AxSpA patients were included in the study. The rate of fulfilling the D2T criteria was 22.9% (n=38) among AxsPA patients treated with biological agents. The potential D2T criteria were met by 23.2% of ankylosing spondylitis and 20.8% of nonradiographic AxSpA patients. Baseline characteristics, such as sex, age, diagnosis age, occupation, and education, of D2T patients were not statistically different from other patients. The prevalence of fibromyalgia was higher in D2T patients (p<0.001). Disease activity indices and acute phase response indicators were higher and quality of life was worse in D2T patients. Conclusion: There was a considerable amount of AxSpA patients fulfilling the D2T criteria despite new and effective treatment agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.